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Abstract
Using newer vaccine platforms which have been effective against malaria in rodent models, we tested five immunization
regimens against Plasmodium knowlesi in rhesus monkeys. All vaccines included the same four P. knowlesi antigens: the pre-
erythrocytic antigens CSP, SSP2, and erythrocytic antigens AMA1, MSP1. We used four vaccine platforms for prime or boost
vaccinations: plasmids (DNA), alphavirus replicons (VRP), attenuated adenovirus serotype 5 (Ad), or attenuated poxvirus
(Pox). These four platforms combined to produce five different prime/boost vaccine regimens: Pox alone, VRP/Pox, VRP/Ad,
Ad/Pox, and DNA/Pox. Five rhesus monkeys were immunized with each regimen, and five Control monkeys received a mock
vaccination. The time to complete vaccinations was 420 days. All monkeys were challenged twice with 100 P. knowlesi
sporozoites given IV. The first challenge was given 12 days after the last vaccination, and the monkeys receiving the DNA/
Pox vaccine were the best protected, with 3/5 monkeys sterilely protected and 1/5 monkeys that self-cured its parasitemia.
There was no protection in monkeys that received Pox malaria vaccine alone without previous priming. The second
sporozoite challenge was given 4 months after the first. All 4 monkeys that were protected in the first challenge developed
malaria in the second challenge. DNA, VRP and Ad5 vaccines all primed monkeys for strong immune responses after the Pox
boost. We discuss the high level but short duration of protection in this experiment and the possible benefits of the long
interval between prime and boost.
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Introduction
Malaria infects over 200 million people annually and causes
almost 1 million deaths [1]. An effective vaccine against malaria
would be a valuable public health tool, complementing anti-
malaria drugs, vector control and environmental modification.
Despite intensive research no malaria vaccine is commercially yet
available. The vaccine farthest along in field testing [2]is based on
a single malaria antigen, and is not as effective as experimental
radiation attenuated whole parasite vaccines [3–8]. When immune
responses to the protective irradiated parasite vaccines are
analyzed, no single target antigen has been identified that explains
the full extent of host immunity[9]. This suggests that the
protective vaccines work by the summation of many immune
responses against multiple antigens on the parasites[9].
Our approach to vaccine development is to develop a multi-
antigen malaria vaccine, mimicking the radiation attenuated
whole parasite vaccines. However, until recently there has been no
animal model allowing the efficacy testing of vaccines against the
pre-erythrocytic stages of the human malaria parasite P. falciparum.
One group in South America has shown that an Owl monkey can
be reproducibly infected with sporozoites of P. falciparum [10–12].
However access to these protected primates is restricted making
this model difficult to replicate elsewhere. While murine malaria
models are invaluable for basic laboratory testing, they may not
accurately predict human vaccine immunogenicity or efficacy.
Furthermore there are no reliable immune correlates of protection
for malaria vaccines, so immunogenicity studies without the results
of malaria challenge are potentially misleading. Attempting to
avoid these difficulties, we have chosen to test malaria vaccine
strategies in the P. knowlesi/rhesus monkey system.
P. knowlesi is a natural infection of Macaca fasicularis
(cynomolgus) monkeys[13], but also infects humans in South East
Asia[14,15]. P. knowlesi sporozoites are highly infectious for many
primates including M. mulatta (rhesus) monkeys with 100 P.
knowlesi sporozoites given iv reliably infecting rhesus monkeys in
our facility. After the P. knowlesi sporozoite invades the
hepatocyte, merozoites are released into the bloodstream 4–5
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days later, comparable to the 5–6 day hepatic development of P.
falciparum in humans. P. knowlesi takes only 24 hours to complete
its growth cycle in the red blood cell, as compared to 48 hours for
P. falciparum, and exponential growth of P. knowlesi often leads to
parasitemias over 50% that can be fatal in rhesus. If the initial
surge of parasites does not kill the host, P. knowlesi becomes a
chronic low-grade infection with reproducible spikes in parasit-
emia due to antigenic variation[13,16], similar to chronic P.
falciparum infection in humans. P. knowlesi infection can be cured
with chloroquine, and monkeys can be successfully re-infected
with P. knowlesi sporozoites 4–6 times before significant blood
stage immunity is evident ([13] and Weiss, unpublished data),
which allows for repeat sporozoite challenges to assess the duration
of vaccine protection.
Our goal in designing this experiment was to find a more potent
malaria vaccine than the DNA/poxvirus heterologous combina-
tion which we have tested previously [17–19]. The vaccines we use
combine four malaria antigens: the circumsporozoite protein
(CSP), sporozoite surface protein 2 also called thrombospondin-
related adhesion protein (SSP2 or TRAP), apical merozoite
antigen-1 (AMA1) and merozoite surface protein 1 (MSP1). We
refer to this four antigen combination as Pk4. Previously the best
protection we have seen in rhesus monkeys was from a Pk 4
‘prime-boost’ vaccine using DNA plasmids followed by recombi-
nant poxvirus. In this experiment, 2/11 (18%) animals were
sterilely protected, with an additional 7/11(63%) showing blood
stage protection [18]. However, our studies of this vaccine have
highlighted several limitations. First, there was little immune
response detectable in the peripheral blood after the DNA
vaccinations, which made us wonder if better priming before viral
boost would be more efficacious. Secondly, protection by the
vaccine waned quickly, and there was little efficacy to a second
malaria sporozoite challenge given three months after the first
challenge. Also, we did not have the reagents to measure immune
responses to all four antigens in the Pk4 vaccine.
The present study uses the Pk4 antigens to compare priming
with three different vaccine modalities before poxvirus (Pox) boost:
DNA plasmids, recombinant adenovirus 5 (Ad5) [20,21], and
recombinant alphavirus-derived viral replicon particles (VRPs)
[20,21]. The DNA plasmids and poxviruses constructs used in this
study are the same as used in our previous published work [17].
Our group has tested both VRP and Ad5 malaria vaccines in
mice, and has found them to be as good as or better than DNA
vaccines for priming before a poxvirus boost ([22] and Doolan
unpublished data). Our goal was to evaluate these vaccine
technologies in a primate malaria model where vaccine responses,
host-parasite interactions and protective efficacy may be better
predictors of results in humans than can be achieved with rodent
malaria models. We also developed reagents to test immune
responses to all 4 P. knowlesi vaccine antigens in order to study
their association with protection.
Materials and Methods
Animals
Rhesus monkeys (Macaca mulatta) descended from Chinese stock
were used for this experiment. Animals were obtained by and
housed at the Walter Reed Army Institute of Research/Naval
Medical Research Center (WRAIR/NMRC), Silver Spring, MD.
Animals were selected to be in general good health, and to have no
history of prior exposure to malaria. Prior to selection for the
studies, serum specimens from all animals were tested in IFAT
assays against P. knowlesi sporozoites and P. knowlesi infected red
cells, and all animals with positive serum titers at dilutions of 1:80
or higher were excluded. The experiment was conducted
according to Guide for the Care and Use of Laboratory Animals 1996.
The experiment required 6 groups of 5 monkeys each (see Table 1).
The 30 selected monkeys were first stratified by age, sex, and
weight and then randomly assigned to groups. This resulted in the
6 groups being closely matched, with mean age 6.4 years (SD 0.2)
and mean weight 5.2 kg (SD 0.2). There were 2 females and 3
males in each group.
Ethics Statement
Animal use in this study was approved by the WRAIR/NMRC
Institutional Animal Care and Use Committee. The WRAIR/
NMRC animal facility is AAALAC accredited and animals are
housed and cared for according to its guidelines. In this study the
major risk to the animals was from the malaria infection. Harm
from malaria infection was minimized by treating with anti-
malarial drugs at a parasitemia level low enough to prevent serious
illness.
DNA plasmid vaccines
The DNA plasmid vaccines encoding Pk4 genes have been
previously described [17]. Briefly, DNA sequences encoding the
full-length genes from the P. knowlesi H strain of CSP, SSP2, and
AMA-1 and the 42 kD C terminal fragment of MSP-1 were
cloned into the VR1020 mammalian expression vector (Vical Inc,
San Diego CA). This vector contains a CMV promoter, and a
TPA signal sequence. Each gene was cloned into a separate
plasmid. Recombinant DNA plasmids were produced by Vical,
Inc and contained less that 0.6 EU of endotoxin per mg and were
at least 80% super coiled. Plasmids were diluted in PBS pH 7.2
prior to injection.
Viral vectors
The same sequences of the Pk4 genes were cloned into 3
different viral vectors: VRP, Ad5, and Pox. Each P. knowlesi
antigen was cloned into separate virus vector.
The Pox vaccines encoding P. knowlesi genes have been
previously described [17,18]. Briefly, the same four P. knowlesi
DNA sequences, which were used to construct the P. knowlesi
DNA plasmids, were cloned into the COPAK poxvirus immuni-
Table 1. Immunization regimens.
Groupa Vaccinationsb
wk 0 wk 4 wk 16 wk 55 wk 60 wk 62
Control - - - - pPoxf challengeh
Pox - - - - Poxg challenge
VRP/Pox VRPc VRP VRP - Pox challenge
VRP/Ad VRP VRP VRP - Ad5 challenge
Ad/Pox - - - Ad5d Pox challenge
DNA/Pox Plasmide Plasmid Plasmid - Pox challenge
aRhesus monkeys 5 animals per group.
bVaccines are mixtures of vectors expressing the individual antigens PkCSP,
PkAMA1, PkSSP2, and PkMSP1.
cRecombinant VRP, 56107 IU/dose each antigen.
dRecombinant Ad5 vectors, 2.561010 particles each antigen.
eRecombinant plasmid vaccine 1 mg/dose each antigen.
fParental pox virus without antigen inserts, 86108 pfu total.
gRecombinant pox virus, 26108 pfu/dose each antigen.
hChallenge with 100 Pk sporozoites iv 12 days after last vaccination.
doi:10.1371/journal.pone.0006559.t001
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zation vector (Virogenetics, Troy, N.Y). COPAK is derived from
the Copenhagen strain of vaccinia virus. The recombinant
alphavirus derived VRP particles for the Pk4 vaccine were
constructed and produced by AlphaVax, Inc (Research Triangle
Park, NC), and the recombinant attenuated Ad 5 for the Pk4
antigens were produced by the GenVec, Inc (Gaithersburg, MD).
Immunization regimens
Five Pk4 malaria vaccine regimens were compared to a mock
control vaccine in this experiment (Table 1). At the time of each
injection, the four antigen vaccines (either DNA or viruses) were
mixed and then given im in the right quadriceps muscle in a total
volume of 1 ml. DNA injections were given by a needle-free
injection system Biojector 2000 (Bioject, Inc, Tualatin, OR), while
all other injections were with #20 gauge needle and syringe. As
seen in Table 1, groups received either no priming injections, or
were primed with DNA plasmids, VRPs, or Ad5. DNA priming
injections contained 1 mg of each of the four Pk4 plasmids, and
were given at weeks 0, 4, and 16. VRP priming injections
contained 56107 infectious units (IU) encoding each Pk4 antigen,
and were also given at weeks 0, 4, and 16. The Ad5 priming
injection contained 2.561010 particles encoding each Pk4 antigen
and was given at week 55.
All monkeys were boosted at week 60. The Control group was
given 86108 pfu of parental COPAK virus lacking a transgene
insert. The four groups receiving Pox vaccine were given a mix of
26108 pfu of each of four COPAK viruses encoding one of the
four Pk4 antigens. The one group boosted with Ad5 received a
mix of 2.561010 particles of each of the four Ad5 viruses encoding
one of the four Pk4 antigens (same dose as the Ad5 prime).
Malaria sporozoite challenges and parasitemia
measurement
The first P. knowlesi sporozoite challenge was given on day 12
after viral boost (week 62). Our initial plan was to challenge 2–4
weeks after viral boost as we had done in our previous studies [17–
19]. However, the challenge was done two days early when it
appeared that this was the best date to obtain infectious
sporozoites from our mosquitoes. P. knowlesi H strain sporozoites
were grown in Anopheles dirus mosquitoes. Sporozoites were
harvested 14 days after mosquitoes had fed on an infected rhesus
monkey. Harvesting was by the Ozaki method. Sporozoites were
diluted in E199 medium with 5% normal rhesus serum and
counted with a hemocytometer. 100 sporozoites in a total volume
of 1 ml were injected IV. A random challenge order was used for
monkeys from different groups, with the exception that the first
and last monkeys challenged were from the Control group. The
challenge took place over the course of four hours.
Beginning 6 days after sporozoite challenge, each day at 1 PM
blood was taken by ear prick. P. knowlesi infections are highly
synchronized in the blood. Before noon parasites are schizonts, up
to half of which may adhere to blood vessels making counts of
circulating parasites inaccurate. With low levels of parasitemia,
most schizonts rupture around mid-day to produce a new crop of
ring forms. Taking blood samples at 1pm avoids underestimating
parasite load during the early days of infection. At higher
parasitemia levels, schizont rupture is often delayed several hours.
If many schizonts are present in the 1 PM specimen, blood smears
were repeated later in the day to get accurate parasite counts.
Blood was prepared for thin and thick malaria smears using
Giemsa stain at pH 7.01 using standard methods [23] For thin
smears, 20,000 red cells were examined. For thick smears,
0.025 ml of blood was examined. These data was used to calculate
the percent infected red blood cells. Animals were followed for 40
days after challenge. To prevent death of animals, when
parasitemias exceeded 2% monkeys were treated by IM injection
of chloroquine hydrochloride 20 mg/kg on day 1 and 10 mg/kg
on days 3 and 4. Forty days after the first sporozoite challenge all
previously untreated monkeys received chloroquine to eliminate
any possible undetected malaria infections prior to rechallenge.
The second P. knowlesi sporozoite challenge was given four
months after the first sporozoite challenge using the same
procedures for infection and follow-up of parasitemias.
Blinding for antibody and T cell assays. Operators
conducting the antibody and T cell assays were not aware of the
vaccination group or the parasitemia status of animals when they
performed the assays. When T cell assays had to be run in batches,
a study investigator who was not involved in the in vitro testing
selected the samples, such that animals from all groups were
included in every run to exclude inter-group bias.
Antibody ELISA assay
Plasma sample was tested by ELISA for IgG titer using each of
the four P. knowlesi antigens used in the immunization studies as
capture antigens. Capture antigen for P. knowlesi CSP was a
synthetic peptide of 36 amino acids representing 3 copies of the 12
aa repeat motif GDGANAGQPQAQ. Capture antigen for the
other three proteins consisted of full length P. knowlesi SSP2, full
length P. knowlesi AMA-1 ectodomain and the P. knowlesi MSP-1
42 kD fragment, respectively, each produced by in vitro synthesis
using the Rapid Translation System RTS 500 E. coli HY kit
(Roche Diagnostics Corporation, Indianapolis, IN). These capture
antigens were used at concentrations of 1 to 4 micrograms per ml
in PBS pH 7.2 in Immulon II 96 well plates (Dynex Technologies
Inc., Chantilly, VA). Plates were blocked with 5% milk powder in
PBS for 2 hours. Plasma samples were diluted in 3% non-fat dry
milk in PBS and incubated in plates at room temperature for 4–
18 hours. Peroxidase-labeled goat anti-human IgG (H+L) (Kier-
kegard Perry Laboratories, Gaithersburg MD) at a 1:10,000
dilution in 3% non-fat dry milk was added for 1 hour, and subtrate
was ABTS (Kierkegard Perry Laboratories). OD was read using a
SPECTRA MAX 190 ELISA reader (Molecular Devices Corp.,
Sunnyvale, CA). Endpoint titer for each sample was the highest
plasma dilution at which the OD was equal or greater than 3-fold
the value of plasma from naı¨ve monkeys.
Immunofluroescence Antibody titers (IFAT) against
whole parasite preparations
For each animal, plasma from five days before the first
sporozoite challenge was evaluated in IFAT against both P.
knowlesi air dried sporozoites and P. knowlesi infected red blood
cells as previously described [24]. Results were the last dilution of
plasma at which fluorescence could be seen.
Antigens for in vitro studies of T cells
For in vitro T cell studies of the four P. knowlesi strain antigens,
we restimulated cells using synthetic peptides for the CSP and
AMA1 antigens, and recombinant proteins for the SSP2 and
MSP1 antigens. For all studies, negative control wells were run
with medium alone, and positive control wells were run with
concanavalin A. Synthetic peptides for the CSP and AMA1
antigens were produced by Pepscan (Lelystad, The Netherlands).
Each peptide was 15 amino acids long with 10 amino acids
overlapping the adjacent peptide, and the peptide series covered
the entire length of each P. knowlesi protein. The CSP pool
contained 42 peptides and the AMA1 pool contained 104
peptides. The final concentration of each individual peptide in
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the pool was 2.5 mg/ml for the CSP and 1.2 mg/ml AMA1. These
concentrations were selected based on our previous studies, and
testing with samples from a small number of positive and negative
control samples.
The recombinant P. knowlesi SSP2 and MSP1 (42 kD) proteins
used for in vitro T cell restimulation were generated using an in
vitro wheat-germ cell free expression system. This protein
expression method has been described in detail[25–27]. Briefly,
transcription of mRNA was achieved using SP6 RNA polymerase
(Promega, Madison, WI). The reaction mixture resulting from
transcription is then directly used as mRNA source in the
translation step. Proteins were translated using a cell-free bilayer
system [26], where the translation reaction is separated from
translational substrate buffer by carefully overlaying in a 6-well
multi-well plate. Then the plate was incubated at 26uC for
overnight. Proteins from the reaction were bound to a glutathione
sepharose 4B column (GE Healthcare Bio-Sciences, Piscataway,
NJ), washed with PBS, and then the column was treated with TEV
protease (Invitrogen, 60 U/column) at 30uC for 3 hrs. Proteins
were eluted with PBS and fractions were analyzed by 12.5% SDS-
polyacrylamide gel stained with CBB. Aliquots were stored at
280uC and proteins were used at a final concentration of 5 mg/ml
in in vitro T cell studies.
IFN-c ELISPOT assay
For in vitro T cell studies, PBMC were isolated from peripheral
blood by centrifugation over ficoll and preserved in liquid
nitrogen. Cells from all time points for each animal were run on
the same day to facilitate comparisons.
The assay for rhesus IFN-c was modified from our previous
method [28,29]. In brief, PVDF-96 well plates (Millipore
Corporation, Bedford, MA) were coated with anti-human IFN-c
(clone GZ-4, Bender Med Systems, Burlingame, CA) incubated
overnight at 4uC, blocked and washed. Cryopreserved PBMC
were rested overnight after thawing, and 26105 cells added per
well. Quadruplicate cells were restimulated with one of the four P.
knowlesi H strain antigens (as described above), or controls.
ELISPOT plates were incubated for 18 hrs at 37uC in an
atmosphere of 5% CO2. The IFN-c spot-forming cells (SFCs) were
counted using an AID ELISPOT reader (Cell Technology, Inc,
Columbia, MD, USA). Responses are presented as the mean
number of net SFCs per million cells in stimulated wells minus the
mean number of spots in medium controls. The major differences
from our previous methods are the resting of the PBMC after
thawing, the use of PVDF instead of MAIP plates, and counting of
spots with the AID ELISPOT reader.
Intracellular cytokine staining and flow cytometric
studies
All reagents for the intracellular cytokine staining were
purchased from BD Bioscience (San Jose, CA) unless otherwise
mentioned. A total 0.5-16106 cryopreserved PBMC were plated
per well in U-bottomed 96-well plates, with 1 mg/ml anti-human
CD28 (Clone CD28.2) and 1 mg/ml anti-human CD49d (Clone
9F10) antibodies with or without antigen. Malaria antigens and
positive and negative control antigens were the same as for the
ELISPOT studies. Brefeldin A was added at 10 mg/ml at 2 hrs
after initial incubation, and plates then incubated an additional
14-hrs at 37uC in an atmosphere of 5% CO2. The cells were
stained with one or more of the following antibodies: CD3-PE-
Cy7, CD4-Alex430, and CD8-APC-Cy7. After the surface
staining, cells were permeabilized in 100 ml CytoFix/Cytoperm
buffer for 20 min, and then stained with anti- IFN-c- FITC (Clone
B27), and anti-IL2-APC(Clone MQ1-17H12), for 45 min on ice in
the dark. The stained samples were analyzed using the LSR-II
flow cytometer (Becton Dickinson Immunocytometry Systems,
San Jose, CA). The expression level of intracellular cytokines was
presented as the percentage of stained cells in gated cell
populations minus background responses in the absence of
antigen. The non-specific background was generally between
0.001–0.05%.
Statistical analyses
Parasitemia outcomes were analyzed using Kaplan-Meier
survival curves and the Log rank test has been used to compare
survival curve for two or more groups. Immunogenicity of vaccine
groups was analyzed using ANOVA and Tukey’s Adjusted
Significant Difference Test. We used the Cox Proportional
Hazard model to analyze effects of immune responses on
protection against malaria.
Results
Effect of vaccinations on parasitemias
Figure 1 shows the parasitemia curves for all monkeys after the
first sporozoite challenge. Each of the panels shows animals that
received a different vaccine. In the Control group (Figure 1A), the
first blood stage parasites were detected between days 8 to 10 (mean
8.6 days) and animals required drug treatment for parasitemia
exceeding 2% between days 10 to 12 (mean 10.8 days). This is
consistent with our previous studies using the 100 P. knowlesi
sporozoite challenge in rhesus monkeys [17–19]. Animals receiving
only recombinant Pk4 Pox vaccine 12 days before challenge
(Figure 1B) had parasitemias similar to the Control group, with no
protection against sporozoite or blood stage parasites.
Compared with the Control groups, monkeys receiving the
VRP/Pox regimen (Figure 1C) had a 2.4 day delay to first
parasitemia (mean 11 days) and a 3.2 day delay to parasit-
emia.2% (mean 14 days). Similar delays to the first parasites
being detected were seen in the VRP/Ad group (Figure 1D), with
monkey #252 having an unusual pattern of infection. This animal
did not have detectable parasites in thick or thin malaria blood
films until days 15–19, when single parasites were observed
intermittently. Then, starting on day 20, parasitemia rose steadily
for one week, peaking at 1%, followed by a decline that occurred
in the absence of drug treatment. We suspect this animal was
parasitemic at a level below detection prior to day 15, and then
had a increase in parasites due to antigenic variation [30], a
pattern of recrudescence well known in P. knowlesi infections and
one we have observed previously in our own studies [17,18]. The
control of parasitemia below lethal levels without need of drugs we
term ‘self-cure,’ although it is likely that blood stage parasites
remain at very low levels after they fall below the threshold
detectable by microscopy.
Figure 1E shows results from the Ad/Pox vaccine group. For
three of the animals in this group there was a modest 0.9 day delay
in day to first parasitemia (mean 9.5 days) and 1.5 day delay in the
day.2% level (mean 12.3 days), relative to Controls. A fourth
animal reached 1% parasitemia and then self-cured. The fifth
animal never developed detectable parasitemia during the 40 days
of follow up. We think that this animal was sterilely protected by
the Ad/Pox vaccine and never had P. knowlesi parasites exit the
liver and infect red blood cells, because there were no later spikes
of recrudescent parasitemia (as observed in the self-cure monkey
#252 from Panel D) during the 40 days of follow-up.
Figure 1F shows the parasitemias of the DNA/Pox vaccine
group. Three of five monkeys were sterilely protected, with 2
monkeys showing a 0.9 day delay in first day of parasitemia (mean
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9.5 days). One of the two infected animals controlled its initial
parasitemia at 1% and then self-cured, while the other exceeded 2%
parasitemia on day 12. We have never previously sterilely protected
such a high proportion of animals given any Pk4 vaccine. We
discuss possible reasons for this high level of protection below.
Fig. 2a shows Kaplan-Meyer curves of the percentage of
animals in each group having parasites detected in the blood by
day after challenge. Figure 2b is a similar graph showing the
percentage of each group exceeding 2% parasitemia by day after
challenge. The DNA/Pox group is the only vaccine group that
had any endpoints statistically different from the Control group
(p = 0.06 and 0.02 for day of first parasitemia and.2%
parasitemia respectively, Log-rank Test). The other vaccine groups
appear less protective than the DNA/Pox vaccine but differences
do not reach statistical significance.
Pk4 vaccine effects against specific stages of the malaria
lifecycle.
Because the Pk4 vaccine contains antigens that are expressed in
sporozoites, liver stages, and blood stages of malaria, it is difficult
to assign protective roles to particular vaccine components. CSP
and SSP2 are found on sporozoites and in early hepatic stages.
AMA1 and MSP1, which are expressed during late hepatic stages
and merozoites, could contribute to protection at both the hepatic
and blood stages of infection. In addition, there is evidence that
AMA1 is present in sporozoite[31]. The time to first detection of
parasites in the blood could be increased by vaccine effects at
several points in the life cycle: by inhibition of sporozoite invasion
of liver cells, by killing of infected hepatocytes or prolongation of
hepatic parasite maturation, or by inhibition of parasite replication
in red cells. Because a slowing of parasite growth provides more
time for induction of immune responses to the blood stages of the
parasite, delays in the early phases of infection could also affect
peak parasitemias. Thus prolongation of either endpoint (time to
first parasite detected in the blood or time to reach.2%
parasitemia) may indicate a mixture of stage-specific and
antigen-specific effects.
However, two outcomes have clear relationships to protection
against specific stages of the parasite life cycle. The first is sterile
protection. On the assumption that the release of any parasites
Figure 1. Daily parasitemias from individual monkeys after sporozoite challenge. Panel A, Control group: average parasitemia levels of 5
individual animals was presented as a thick grey line (Cont.) and is included in all 6 panels for comparison; B, Pox group; C, VRP/Pox group; D,VRP/Ad
group; E, Ad/Pox group; F, DNA/Pox group; The dotted line in each panel shows the parasitemia level 2% at which we treated animals with anti-malaria
drug. One monkey (206) in Panel E, and 3 monkeys (219, 249 and 251) in Panel F that had no detectable parasitemia are shown as horizontal lines.
doi:10.1371/journal.pone.0006559.g001
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Figure 2. Kaplan-Meyer curves showing parasitemia endpoints for the six experimental groups. Panel A. shows the percentage of
animals in each vaccine group without parasites detected in blood. Panel B. shows the percentage of animals with parasitemia below 2%. X axis
shows day since sporozoite challenge. In each panel the DNA/Pox group shows the highest level of protection.
doi:10.1371/journal.pone.0006559.g002
Malaria Vaccines in Rhesus
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from the liver will eventually lead to a patent infection (such as
animal 252, Panel D, Figure 1), we believe that the four animals that
never had parasitemia provide evidence for complete protection
against sporozoites and liver stages of the parasite. The second
outcome with a straightforward interpretation is self-cure. Three
animals became infected but limited their parasitemia without need
for drug treatment, indicating an effective immune response against
the blood stages of the parasite. Even prior to their decline in
parasite counts, the self-cure animals showed a slower rate of growth
than Controls (Figure 3). Between days 1–2 and 2–3 of parasitemia,
the mean rate of increase for the 5 Control animals was 0.03% and
0.37% per day, a nearly exponential progression. For the 3 self-cure
monkeys, the mean rate of increase between days 1–2, 2–3, and 3–4
was 0.07%, 0.11%, and 0.15%, a more constant rate of growth. We
believe that immune responses to blood stage antigens must have
caused these slower growth rates.
Immunogenicity of different vaccine regimens
We measured circulating antibody and T cell responses to each
of the four P. knowlesi antigens in the vaccine. Antibody measures
included ELISA against each of the four vaccine antigens, and
IFAT against whole fixed sporozoites and infected red cells.
ELISA data is shown in Figures 4a. IFAT data is similar to ELISA
data, with high titers to CSP or SSP2 giving high IFAT titers
against sporozoites, and high ELISA titers to AMA1 or MSP1
giving high IFAT titers against infected red cells (data not shown).
T cell responses were measured by IFN-c ELISPOT assay and
flow cytometric analysis of intracellular IFN-c and IL-2 produc-
tion. Data from the on IFN-c ELISPOT on PBMCs are shown in
4b. Data from the flow cytometric studies were comparable to the
IFN-c ELISPOT (data not shown).
No significant immune responses were detected in samples from
pre-vaccination samples. Three weeks after the last of three
vaccinations with either Pk4 VRPs or Pk4 DNA plasmids, we
detected no statistically significant immune responses to any of the
four antigens by ELISA or ELISPOT. In contrast, three weeks
after a single dose of Pk4 Ad5 (Figure 4a), there were significant
increases in antibody responses to three of four antigens CSP,
SSP2, and MSP1 p,0.05). The Ad5 vaccine also induced
measurable ELISPOT responses to each of the four antigens in
some animals(Figure 4b), although the group differences were not
statistically significant.
All monkeys received a viral ‘booster’ vaccination at week 60
with either a control poxvirus (Control group), the Pk4 Ad5 viruses
(VRP/Ad group), or the Pk4 poxviruses (four remaining groups).
Blood was taken seven days later for measurement of immune
responses and sporozoite challenge occurred 5 days after this
blood sampling.
In the samples taken 7 days after the final vaccination, there
were significant differences between the experimental groups in
ELISA and ELISPOT responses to each of the four vaccine
antigens (analysis by ANOVA, results not shown). We then
compared immune responses with the Control group by T test
using Tukey’s Adjustment for multiple comparisons (Table 2). The
group vaccinated with control Pox or Pk4 Pox (unprimed) seven
days previously had no immune responses significantly different
from Controls. In contrast, all prime/boost vaccine groups
developed immune responses to some or all vaccine antigens that
were statistically different from Controls, but there were no
statistically significant differences between any prime/boost
vaccine groups. Of note, the Ad/Pox and DNA/Pox vaccines
were the only ones which induced significant ELISPOT responses
to CSP, and these two vaccine groups were the only two which
contained sterilely protected animals. The DNA/Pox group with
3/5 animals sterilely protected was the only vaccine group which
produced statistically significant antibody responses to CSP.
Association between immune responses and protection
against sporozoite challenge
We were interested to know if the magnitude of any immune
response was associated with protection against malaria indepen-
dent of which vaccine the animal received. We approached this
question in two ways. First we analyzed immune responses of all
30 monkeys with respect to the two protective endpoints, ‘day of
first parasitemia’ or ‘day.2% parasitemia’. As discussed previ-
ously, we believe that immune responses to both pre-erythrocytic
and erythrocytic stage antigens could contribute to any protective
effect identified by these two endpoints. In the second approach,
we focused on the four sterilely protected monkeys (sterile
protection reflecting immune responses targeting pre-erythrocytic
stages) and the three monkeys that self-cured their parasites (self-
cure reflecting immune responses targeting blood stages), com-
paring immune responses in these protected animals to the other
monkeys in the same vaccine groups.
To analyze the relationship between immune responses of all 30
monkeys and protection we used Cox Proportional Hazard
analysis. Table 3 shows that considered one at a time many
immune responses to vaccine antigens were significantly associated
with protection. All ELISPOT responses except for CSP had
important effects on both day to first parasite and day.2%
parasitemia. We have found this same lack of correlation of
ELISPOT responses of PBMC to CSP in previous P. knowlesi
vaccine studies [19]. For the ELISA data, both SSP2 and MSP1
responses had a significant effect on both protective endpoints.
However, when we fit models using the immune responses to the
four vaccine antigens simultaneously, neither ELISA nor ELI-
SPOT responses to any one vaccine antigen were significantly
correlated with either protective endpoint (data not shown).
In a second set of analyses, we focused on the immune responses
in the sterilely protected and self-cure animals. We compared the
immune responses to all four vaccine antigens of these protected
animals with those of the other non-protected monkeys in the
same vaccine groups. Comparing responses of the four sterilely
protected monkeys with the six unprotected animals in the DNA/
Pox and Ad/Pox groups, only the MSP1 ELISA and ELISPOT
showed a trend toward higher values in the sterilely protected
monkeys but this was not statistically significant (data not shown).
There were also no differences in immune responses between the
Figure 3.Mean parasitemias of the 5 Control monkeys compared
to the 3 monkeys from vaccine groups which contained their
parasitemia below 2%. The X axis is normalized so day 1 is the first day
parasites were detected in the blood for each animal. Monkeys which
controlled their parasitemias had slower growth rates.
doi:10.1371/journal.pone.0006559.g003
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Figure 4. Immune responses induced by vaccinations against the four vaccine antigens. Plasma samples were assayed by ELISA (Panel A),
and PBMCs were assayed -forming cells by Elispot (Panel B). Data is presented for 3 timecfor IFN points: ‘Pre’ = pre-immunization; ‘Prime’ = 3 weeks
after the last priming immunization; and ‘Boost’ = 7 days after viral boost immunization which was 5 days before challenge. Mean of 5 animals in each
group was presented as a rectangle. Data for individual animals is presented as triangles. Immune responses in the Pox only group were lower than in
all groups receiving prime/boost vaccines.
doi:10.1371/journal.pone.0006559.g004
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three self-cure monkeys, the four sterilely protected monkeys and
the eight unprotected monkeys in the DNA/Pox, Ad/Pox, and
VRP/Pox groups (data not shown). Thus, neither analysis allows a
clear dissection of the protective roles of the different vaccine
antigens. This is possibly explained by the fact that all immune
responses were highly correlated with each other, so statistical
separation of effects was not possible.
Intracellular cytokine expression of CD4 and CD8 cells
To further understand the T cell responses to the four vaccine
antigens, we used flow cytometry to study the CD4 and CD8
phenotype of T cells responding after in vitro restimulation using
both IFN-c and IL-2 production as measures of immune response.
No increase in CD8+ T cell responses was detected for any of the
four vaccine antigens (data not shown). In contrast, CD4+ T cells
were detected producing IFN-c, IL-2 or both cytokines together in
a pattern similar to that seen in the IFN-c ELISPOT assay (data
not shown). We conclude that the ELISPOT responses from
PBMC are primarily from CD4+ T cells, which has also been the
case in our previous studies of the Pk4 vaccine in rhesus monkeys
[28].
Protection against a second sporozoite challenge
Four months after the first sporozoite challenge, all animals
received a second challenge with 100 P. knowlesi sporozoites given
IV. Figure 5 shows the daily parasitemias for each monkey during
the second challenge. All five Control monkeys became para-
sitemic at a mean 8.4 days after challenge, and all required drug
treatment at mean day 11.4 (Figure 5 panel A). The four monkeys
that were sterilely protected in the first challenge became
parasitemic in the second challenge on day 9 and were treated
on day 12 (Figure 5 panels E and F). Thus the vaccine responses
that protected animals in the first challenge were not maintained
long enough to protect them against the second challenge. Of the
three monkeys which self-cured in the first challenge, two self-
cured after the second challenge (Figure 5 panel D and E) and one
required drug treatment (Figure 5 panel E). One monkey in the
Pox group (223) was protected in the second challenge but not in
the first (Figure 5 panel B). Protection of a monkey only in the
second challenge but not in the first might seem paradoxical. We
believe that this monkey did receive an adequate infectious
challenge in the second round, as there were no technical
problems with the injection. We believe that the most likely
explanation is that the first challenge exposed monkeys to malaria
parasites with multiple antigens that boosted vaccine induced
immune responses. The complication of exposure to parasites after
the first challenge makes further interpretation of protection data
from the second challenge difficult.
Discussion
The goal of this study was to improve upon the Pk4 DNA/Pox
vaccine by replacing the DNA components with VRP or Ad5
vaccines. Unfortunately, while both of these novel vaccines were
able to prime immune responses for boosting neither gave as much
protection as priming with DNA plasmids.
Vaccination with DNA plasmids is potent in mice but much less
effective in primates and humans where very large amounts of
DNA are required to induce small immune responses. In mouse
malaria vaccine studies using PyCSP antigen, VRPs and DNA
have been comparable in priming responses for boosting with
recombinant adenovirus or poxvirus (Doolan, personal communi-
cation). Unfortunately, in the present experiment VRPs were
minimally immunogenic in themselves, and did not prime for
protection with a poxvirus boost as well as did DNA. Although
VRPs were the least effective priming modality we tested, a
comparison with the Pox alone group shows that VRP priming did
enhance protection and immunogenicity.
Recombinant Pk4 adenovirus type 5 vaccines were given to two
groups of monkeys in these experiments: in the Ad/Pox group
they were the prime and in the VRP/Ad group they were the
boost. Comparing immune responses after priming alone (Fig. 4a
and b), we are impressed that after a single priming dose, the
monkeys receiving the Ad5 vaccines were able to mount antibody
and T cell responses to most of the Pk4 antigens. We suspect that
the one month interval between prime and boost for the Ad/Pox
group was not optimal, and that a longer interval might lead to
even better immunogenicity and protection.
Comparing the VRP/Pox and VRP/Ad groups allows us to
assess the value of the Ad5 virus as a booster vaccine. Protection
was at least as good if not better in the VRP/Ad group than the
VRP/Pox group, and immune responses were equivalent. Thus
we believe that the Ad5 provided a boost as potent as the
poxviruses
The most striking finding of this study is the high level of sterile
protection in the monkeys receiving the Pk4 DNA prime/poxvirus
Table 2. Immune responses of vaccine groups prior to
challenge.
Pox VRP/Pox VRP/Ad Ad/Pox DNA/Pox
ELISPOT CSP + +
SSP2 + + +
AMA1 + + + +
MSP1 + + + +
ELISA CSP +
SSP2
AMA1 + + +
MSP1 +
The five vaccine groups compared with the Control group for immune
responses to each vaccine antigen. Analysis used Student’s T test with Tukey’s
Adjustment for multiple comparisons. Crosses (+) indicate that the comparison
with the Control group is statistically significant (p,0.05).
doi:10.1371/journal.pone.0006559.t002
Table 3. Cox Proportional Hazards Analysis of immune
responses and parasitemia.









Crosses (+) show statistically significant effects on protective endpoints when
immune responses are analysed separately. When responses to all antigens are
analysed sim-ultaneously no single immune response is statistically associated
with either protective endpoint.
doi:10.1371/journal.pone.0006559.t003
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boost vaccine in the first challenge. Three of five monkeys (60%)
never developed parasitemia after sporozoite challenge, and of the
two monkeys that did become infected, one cured its parasitemia
without the need for drug treatment. The fact that this protection
was achieved using a DNA/poxvirus vaccine regimen suitable for
humans is especially encouraging. In our previous four challenge
experiments (Table 4), a total of 3/30 monkeys were sterilely
protected by the Pk4 DNA/Pox vaccine, with protection ranging
from 0 to 18%. Comparing the present study with the pooled
results of our previous studies yields an Odds Ratio of 0.074 (95%
CI 0.008, 0.636). Thus it is not likely that the improved protection
is a random fluctuation due to the small number of experimental
animals. Our hypothesis is that the increased protection may be
due in part to the long intervals between vaccine doses used in this
study, as has been seen in rodent malaria vaccine studies [32].
However there are several caveats to be considered when
comparing the present study with our previously published results.
Because we have been working over a period of years, different
Figure 5. Daily parasitemias from individual monkeys after the second sporozoite challenge. Panel A, Control group: average
parasitemia levels of 5 individual animals was presented as a thick grey line (Cont.) and is included in all 6 panels for comparison; Panel B, Pox group;
Panel C, VRP/Pox group; Panel D, VRP/Ad group; Panel E, Ad/Pox group; Panel F, DNA/Pox group; The dotted line in each panel shows the 2%
parasitemia level at which we treated animals with anti-malaria drugs. One monkey (223) in Panel C had no detectable parasitemia is shown as a
horizontal line. The four monkeys which had no detectable parasitemias after the first challenge all developed parasites in the second challenge and
are graphed with black interrupted lines. The three monkeys which self-cured their parasitemias after the first challenge are graphed with thick
stippled lines.
doi:10.1371/journal.pone.0006559.g005
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production batches of plasmid and viral vaccines have been used.
There are also some differences in the vaccine regimens, with the
present study spreading the three priming DNA vaccinations over
4 months, and the study from Rogers et al. [18] including a fourth
DNA dose before poxvirus boosting. Also, although challenge has
always been with 100 P. knowlesi sporozoites the infectivity of
those sporozoites no doubt varied between experiments. Finally,
the rhesus monkeys in our studies have been obtained from several
sources. In our previous studies using the Pk4 vaccine, we have
used rhesus monkeys from breeding colonies founded with rhesus
monkeys of Indian origin. In this study, we used rhesus monkeys of
Chinese origin because Indian origin rhesus were not available at
our institution. Although the immune responses to vaccines of
genetic subgroups of rhesus monkeys may differ [33], in the
absence of an immune correlate of protection we cannot know if
genetic differences are responsible for the improved protection
seen in this experiment. Because of all these concerns, the concept
of longer vaccinations leading to better protection remains a
conjecture which must be directly tested in a future experiment.
We were not able to identify an immune correlate of protection
in this study. The two vaccines, DNA/Pox and Ad/Pox, which
induced the most consistent immune responses to the P. knowlesi
CSP were also the only two vaccines which sterilely protected
monkeys (Table 2). From this, one might expect that the blood of
protected monkeys would have higher antibody or T cell responses
to CSP than non-protected monkeys. However, this was not the
case (Table 3). One explanation for this seeming contradiction is
that immune responses in the blood do not reflect protective
immune responses in tissues. In mice, it has been shown that the
immune responses that correlate with pre-erythrocytic malaria
immunity occur within the liver tissue itself [34]. We think it likely
that similar tissue specific liver immunity is occurring with pre-
erythrocytic immunity in primates and humans as well, and that
these immune events may not be easy to detect in the peripheral
blood. We are undertaking studies of immune responses in the
monkey liver to examine this concept.
Using flow cytometry, we were able to measure antigen specific
responses from CD4+ T cells but we did not detect antigen specific
CD8+ T cell responses. This is consistent with our previous studies
of the Pk4 DNA/Pox vaccine [19,28]. We had hoped that the
VRPs or Ad5 viruses would be able to induce CD8+ T cell
responses but this was not the case. CD8+ T cells are important
immune effectors against liver stages of malaria in mice [35–37]
and monkeys (Weiss, unpublished data) protectively immunized
with radiation-attenuated malaria sporozoites. We believe that a
vaccine which induces CD8+ T cell effectors may have increased
efficacy against malaria liver stages.
The biggest failing of the P. knowlesi vaccines has been the short
duration of protection: no sterilely protected animals in the first
sporozoite challenge were sterilely protected in the second challenge
four months later. This has also been the case in all of our previous
studies. Lacking an immune correlate of protection, our vaccine
development strategy is to improve the magnitude and longevity of
all immune responses to malaria vaccine antigens, and to induce
CD8+ effector T cells. Our next plan is to replace DNA priming
with recombinant malaria proteins in novel adjuvants [38,39]. We
hope these next generation priming vaccines will allow stronger and
longer lasting immune responses after boosting with recombinant
viral vaccines, and a corresponding lengthening of vaccine efficacy.
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Table 4. Summary of Sterile Protection in Five Pk4 DNA/Pox Vaccine Studies.
Trial N = Sterile # Sterile %
a DNA1 DNA2 DNA3 Pox 5 3 60
day 0 28 96 420
b DNA1 DNA2 DNA3 DNA4 Pox 11 2 18
day 0 30 60 280 310
c DNA1 DNA2 DNA3 Pox 5 0 0
day 0 30 60 207
d DNA1 DNA2 DNA3 Pox 10 1 10
day 0 30 60 156
e DNA1 DNA2 DNA3 Pox 4 0 0
day 0 30 60 108
Summary of five published vaccine studies in rhesus monkeys using the Pk4 DNA/Pox vaccine and challenge with 100 Pk sporozoites IV. Trial a is the present
experiment. Trial b is from Rogers (18). Trials c and e are from experiment 3 in Weiss (19), Trial d is from experiments 1 and 2 in Weiss (19). N gives the number of animals
receiving the Pk4 DNA/Pox vaccine, and Sterile gives the number of animals which did not develop parasites in the blood. Longer regimens give higher proportion of
sterilely protected animals.
doi:10.1371/journal.pone.0006559.t004
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